Amarin Corp. (AMRN) Tops Q3 EPS by 4c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Amarin Reports Third Quarter 2019 Financial Results and Provides Update on Operations
November 5, 2019 5:00 AM ESTRecord Revenue Levels and Preparations On-Track for Further Expansion
Management to Host Conference Call at 7:30 a.m. ET Today
DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced financial results for the three and nine months ended September 30, 2019 and provided an update on company operations. Key Amarin achievements since its last quarterly report include:
Record total revenue: Reported total revenue of $112.4 million and $286.5... More